Skip to main content
Log in

Platelets and Granulocytes, in Particular the Neutrophils, Form Important Compartments for Circulating Vascular Endothelial Growth Factor

Angiogenesis Aims and scope Submit manuscript

Abstract

The measurement of circulating vascular endothelial growth factor (VEGF) levels as a prognostic factor will gain increasing relevance in the diagnosis and evaluation of treatment in cancer patients. Angiogenesis is an absolute requirement in tumour growth and metastatic disease. In the present study data are presented which indicate that circulating VEGF mainly resides in peripheral blood cells. In 15 healthy volunteers we demonstrated that approximately 34% of the circulating VEGF resides in platelets and approximately 11% in patients with cancer (n= 4). An important part namely 58% in healthy volunteers and 69% in patients with cancer of the total circulating VEGF is contained in granulocytes, particular in the neutrophils, as confirmed by fluorescence-activated cell sorting (FACS). Also an increased VEGF level per granulocyte is found in patients with cancer (77 μg VEGF/l) compared with the healthy volunteers (164 μg VEGF/l). In contrast only 2% was present in plasma. The biological significance of platelet- or granulocyte-derived VEGF is not yet known. Liberation of VEGF from these compartments could well be of importance for tumour angiogenesis. Therefore, future studies on the clinical value of circulating VEGF as a prognostic factor in cancer patients should include measurements of VEGF in peripheral blood cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Senger DR, Galli SJ, Dvorak AM et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983–5.

    PubMed  CAS  Google Scholar 

  2. Ferrara N. Vascular endothelial growth factor. Eur J Cancer 1996; 32A: 2413–22.

    Article  PubMed  CAS  Google Scholar 

  3. Adams J, Carder PJ, Downey S et al. Vascular endothelial growth factor (VEGF) in breast cancer: Comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res 2000; 60: 2898–905.

    PubMed  CAS  Google Scholar 

  4. Oehler MK, Caffier H. Prognostic relevance of serum vascular endothelial growth factor in ovarian cancer. Anticancer Res 2000; 20: 5109–12.

    PubMed  CAS  Google Scholar 

  5. Kumar H, Heer K, Lee PW et al. Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin Cancer Res 1998; 4: 1279–85.

    PubMed  CAS  Google Scholar 

  6. Ugurel S, Rappl G, Tilgen W, Reinhold U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 2001; 19: 577–83.

    PubMed  CAS  Google Scholar 

  7. Matsuyama W, Hashiguchi T, Mizoguchi A et al. Serum levels of vascular endothelial growth factor dependent on the stage progression of lung cancer. Chest 2000; 118: 948–51.

    Article  PubMed  CAS  Google Scholar 

  8. Verheul HM, Hoekman K, Luykx-de Bakker S et al. Platelet: Transporter of vascular endothelial growth factor. Clin Cancer Res 1997; 3: 2187–90.

    PubMed  CAS  Google Scholar 

  9. Webb NJ, Bottomley MJ, Watson CJ, Brenchley PE. Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: Implications for measurement of circulating VEGF levels in clinical disease. Clin Sci (Lond) 1998; 94: 395–404.

    CAS  Google Scholar 

  10. Banks RE, Forbes MA, Kinsey SE et al. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: Significance for VEGF measurements and cancer biology. Br J Cancer 1998; 77: 956–64.

    PubMed  CAS  Google Scholar 

  11. Wynendaele W, Derua R, Hoylaerts MF et al. Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: A key to study an angiogenic marker in vivo? Ann Oncol 1999; 10: 965–71.

    Article  PubMed  CAS  Google Scholar 

  12. Salven P, Orpana A, Joensuu H. Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin Cancer Res 1999; 5: 487–91.

    PubMed  CAS  Google Scholar 

  13. Loken MR, Brosman JM, Ault KA et al. Establishing Optimal Lymphocyte Gates for Immunophenotyping using LeucoGate, Beckton Dickinson Immunocytometry Systems. San Jose, California: Becton Dickinson 1998.

    Google Scholar 

  14. Mohle R, Green D, Moore MA et al. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA 1997; 94: 663–8.

    Article  PubMed  CAS  Google Scholar 

  15. Gaudry M, Bregerie O, Andrieu V et al. Intracellular pool of vascular endothelial growth factor in human neutrophils. Blood 1997; 90: 4153–61.

    PubMed  CAS  Google Scholar 

  16. Scapini P, Calzetti F, Cassatella MA. On the detection of neutrophil-derived vascular endothelial growth factor (VEGF). J Immunol Meth 1999; 232: 121–9.

    Article  CAS  Google Scholar 

  17. Freeman MR, Schneck FX, Gagnon ML et al. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: A potential role for T cells in angiogenesis. Cancer Res 1995; 55: 4140–5.

    PubMed  CAS  Google Scholar 

  18. Katoh O, Tauchi H, Kawaishi K et al. Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation. Cancer Res 1995; 55: 5687–92.

    PubMed  CAS  Google Scholar 

  19. Bottomley MJ, Webb NJ, Watson CJ et al. Peripheral blood mononuclear cells from patients with rheumatoid arthritis spontaneously secrete vascular endothelial growth factor (VEGF): Specific up-regulation by tumour necrosis factor-alpha (TNFalpha) in synovial fluid. Clin Exp Immunol 1999; 117: 171–6.

    Article  PubMed  CAS  Google Scholar 

  20. Griga T, Gutzeit A, Sommerkamp C, May B. Increased production of vascular endothelial growth factor by peripheral blood mononuclear cells in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 1999; 11: 175–9.

    PubMed  CAS  Google Scholar 

  21. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146: 1029–39.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Geke A.P. Hospers.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kusumanto, Y.H., Dam, W.A., Hospers, G.A. et al. Platelets and Granulocytes, in Particular the Neutrophils, Form Important Compartments for Circulating Vascular Endothelial Growth Factor. Angiogenesis 6, 283–287 (2003). https://doi.org/10.1023/B:AGEN.0000029415.62384.ba

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:AGEN.0000029415.62384.ba

Navigation